Injectable Steroids

MASTERON P 100 (Drostanolone Propionate) 100 mg Evo Genetics

Evo Genetics

60,00

In Stock (100 available)

MASTERON P 100 (Drostanolone Propionate) 100 mg Evo Genetics (100 mg) — Drostanolone is the quintessential pre-contest compound — a DHT-derived injectable that produces a granite-hard, deeply striated…

100 in stock

This product is for laboratory research use only. Not for human consumption.

5+ −10%
10+ −15% Best price
Third-Party Lab Report HPLC verified
CoA available on request — email support@vitalquests.org with the batch code from your vial.
HPLC TestedBatch report available
No Labels on BoxPlain brown parcel
Pay the CourierCash on delivery only
Ships TodayOrder before 14:00
€85+ = free shipping
EU warehouse — no customs, no delays
Tracked via DHL / DPD / InPost

Description

Drostanolone (Masteron), Evo Genetics, 100 mg. DHT-class anti-estrogenic anabolic with minimal side-effect burden relative to its visual impact. Low-bodyfat cutting staple; Propionate for EOD schedules, Enanthate for 2×-weekly flexibility.

Key Benefits

  • DHT-derivative — dry, hard, vascular look with no water retention
  • Anti-estrogenic side-activity — mild AI effect
  • Cutting and pre-contest staple, especially at low body-fat
  • Minimal sides at performance doses — clean compound
  • Stacks well with tren, test, and orals for cutting recomp
  • Each unit dosed at 100 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: propionate 300–500 mg/week split EOD or 3×/week; enanthate 400–600 mg/week split twice weekly. Cycles 8–10 weeks (prop) or 10–14 weeks (eno). Pre-contest protocols stretch to final 6 weeks before show.

How It Works

5α-reduced testosterone with a 2α-methyl group. DHT-derivative — does not aromatise. Mild anti-estrogenic activity via aromatase enzyme competition. High AR affinity. Androgenic but not aggressively so at typical doses.

Pharmacokinetics

Propionate ester: plasma half-life ~2 days. Enanthate: ~7 days. Prop needs EOD or M/W/F pinning; eno twice-weekly fine. Steady-state in 2 weeks (prop) or 4 weeks (eno).

Cycle & Stacking Guide

Cutting stack component, 8–14 weeks by ester. Classic pairing: test E 250 mg/week + masteron E 400 mg/week + (optional) tren or winstrol for final weeks. Works best at <15% body fat where the "dry" look actually shows.

Manufacturer Notes

Evo Genetics produces AAS at standard 200, 250, and 300 mg/ml concentrations. Batch verification available through the distributor network.

Storage & Handling

Store upright at 15–25 °C in the original box, protected from light and moisture. Oil-based injectables are shelf-stable for the duration printed on the vial when kept at controlled room temperature. Do not refrigerate — cold thickens the carrier oil and makes drawing/injecting harder. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “MASTERON P 100 (Drostanolone Propionate) 100 mg Evo Genetics”

Your email address will not be published. Required fields are marked *

Drostanolone Propionate

Physical & Chemical Properties for Research Purposes
Chemical structure of Drostanolone Propionate (C23H36O3) for laboratory analysis
2D structural representation · PubChem CID 224004 ↗
Chemical Identity
# CAS Registry Number 521-12-0
Σ IUPAC Name [(2R,5S,8R,9S,10S,13S,14S,17S)-2,10,13-trimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl] propanoate
F Molecular Formula C23H36O3
M Molecular Weight 360.53 g/mol
SMILES CCC(=O)O[C@@H]1CC[C@@H]2[C@H]3CC[C@@H]4CC(=O)[C@@H](C)C[C@]4(C)[C@@H]3CC[C@]12C
InChIKey VDIINQKPRNWKEH-GOGNSEEVSA-N
Melting Point 124-126 °C
Solubility Insoluble in water; soluble in oils
Biological Half-life 2.5 days (IM)
PubChem CID 224004 ↗
Pharmacological Profile
Anabolic Rating 62
Androgenic Rating 25
Aromatization None
Hepatotoxicity None
Detection Time 3 weeks

Clinical Notes

DHT-derived injectable — 2alpha-methyl modification at the A-ring confers resistance to 3alpha-HSD, allowing intact muscle-cell activity. Cannot aromatise. Weak AR binding in skeletal tissue but displaces estradiol from SHBG, increasing free-testosterone fraction of any concurrent testosterone — this is the mechanism behind the hardening clinical picture at low body-fat percentages. Effect is visibly null above 15% body fat; below 12%, the lean-tissue definition response becomes dose-responsive. Propionate ester mandates EOD injection schedule; PIP is common and dose-dependent — low-viscosity MCT or GSO carrier oil reduces it materially. Androgenic effects (scalp, prostate) occur but are limited to DHT-sensitive populations.

Known trade names: Masteron, Drostopro, Mastabol

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.